Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
Authors
Keywords
-
Journal
ONCOGENE
Volume 42, Issue 23, Pages 1875-1888
Publisher
Springer Science and Business Media LLC
Online
2023-05-03
DOI
10.1038/s41388-023-02705-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Splicing is an alternate oncogenic pathway activation mechanism in glioma
- (2022) Robert Siddaway et al. Nature Communications
- Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
- (2022) Andrew B. Lassman et al. CLINICAL CANCER RESEARCH
- Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial
- (2022) D. Williams Parsons et al. JOURNAL OF CLINICAL ONCOLOGY
- The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
- (2022) Pablo Berlanga et al. Cancer Discovery
- Erdafitinib in pediatric patients with advanced solid tumors with fibroblast growth factor receptor (FGFR) gene alterations: RAGNAR study pediatric cohort.
- (2022) Olaf Witt et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
- (2022) Steven Attia et al. Cancer Medicine
- A fusion transcription factor-driven cancer progresses to a fusion-independent relapse via constitutive activation of a downstream transcriptional target
- (2021) Salah Boudjadi et al. CANCER RESEARCH
- Targeting fibroblast growth factor receptors to combat aggressive ependymoma
- (2021) Daniela Lötsch et al. ACTA NEUROPATHOLOGICA
- Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival
- (2021) Riaz Gillani et al. CANCER RESEARCH
- Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
- (2021) Nathalie Gaspar et al. LANCET ONCOLOGY
- Genomes for Kids: The scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing
- (2021) Scott Newman et al. Cancer Discovery
- The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets
- (2021) Cornelis M. van Tilburg et al. Cancer Discovery
- Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer
- (2021) Ikuko Takeda Nakamura et al. npj Precision Oncology
- Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas
- (2021) Ashleigh M. Fordham et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆
- (2021) N. Gaspar et al. ESMO Open
- Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines
- (2020) STEFAN HOLZHAUSER et al. ANTICANCER RESEARCH
- Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
- (2020) Scott Ryall et al. CANCER CELL
- FGF2: a novel druggable target for glioblastoma?
- (2020) Ana Jimenez-Pascual et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Trametinib-based Treatment of Pediatric CNS Tumors
- (2020) Megan R. Paul et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
- (2020) Neevika Manoharan et al. JOURNAL OF NEURO-ONCOLOGY
- LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER
- (2020) F. Duffaud et al. ANNALS OF ONCOLOGY
- Response to trametinib treatment in progressive pediatric low-grade glioma patients
- (2020) Florian Selt et al. JOURNAL OF NEURO-ONCOLOGY
- Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer
- (2020) Marie Wong et al. NATURE MEDICINE
- Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations
- (2020) Samuel W. Brady et al. Nature Communications
- Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia
- (2019) Isabel S. Jerchel et al. Scientific Reports
- Clinical utility of custom-designed NGS panel testing in pediatric tumors
- (2019) Lea F. Surrey et al. Genome Medicine
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
- (2019) Lara E. Davis et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Yohann Loriot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted therapy and disease monitoring in CNTRL-FGFR1-driven leukaemia
- (2019) Lauren M. Brown et al. PEDIATRIC BLOOD & CANCER
- Oncogenic fusion protein BCR-FGFR1 requires BCR-mediated oligomerization and chaperonin Hsp90 for activation
- (2019) Malalage N. Peiris et al. HAEMATOLOGICA
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
- (2019) Martin Schuler et al. LANCET ONCOLOGY
- Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622
- (2018) William B. Slayton et al. JOURNAL OF CLINICAL ONCOLOGY
- The landscape of genomic alterations across childhood cancers
- (2018) Susanne N. Gröbner et al. NATURE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma
- (2018) Timothy McKinnon et al. ONCOGENE
- Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
- (2018) Xiaotu Ma et al. NATURE
- FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p
- (2018) Jinglin Zhang et al. ONCOGENE
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Florence Duffaud et al. LANCET ONCOLOGY
- Fibroblast growth factor receptors as treatment targets in clinical oncology
- (2018) Masaru Katoh Nature Reviews Clinical Oncology
- Emerging Roles of Fibroblast Growth Factor 10 in Cancer
- (2018) Natasha S. Clayton et al. Frontiers in Genetics
- FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1
- (2017) Tingting Huang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The whole-genome landscape of medulloblastoma subtypes
- (2017) Paul A. Northcott et al. NATURE
- Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway
- (2016) Jason T. Huse et al. ACTA NEUROPATHOLOGICA
- Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology
- (2016) Ibrahim Qaddoumi et al. ACTA NEUROPATHOLOGICA
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1
- (2016) Kaito Yoza et al. GENES TO CELLS
- FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors
- (2016) Eileen Shi et al. Journal of Translational Medicine
- Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation
- (2016) K. N. Nelson et al. MOLECULAR CANCER RESEARCH
- Exploring genomic alteration in pediatric cancer using ProteinPaint
- (2016) Xin Zhou et al. NATURE GENETICS
- Pediatric 8p11 eosinophilic myeloproliferative syndrome (EMS): A case report and review of the literature
- (2016) Jay F. Sarthy et al. PEDIATRIC BLOOD & CANCER
- Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
- (2016) Wenya Zhou et al. Oncotarget
- Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles’ Heel of Targeted Therapy
- (2015) Christal D. Sohl et al. ACS Chemical Biology
- Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
- (2015) Gottfried E Konecny et al. LANCET ONCOLOGY
- Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia
- (2015) M S Khodadoust et al. LEUKEMIA
- Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1
- (2015) D Weekes et al. ONCOGENE
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
- (2014) Gang Wu et al. NATURE GENETICS
- Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
- (2014) M. Fernanda Amary et al. Cancer Medicine
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
- (2013) Kai Hung Tiong et al. APOPTOSIS
- Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells
- (2013) Tao Ren et al. CANCER SCIENCE
- Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma
- (2013) Bridget Charbonneau et al. HUMAN PATHOLOGY
- FGF Receptors: Cancer Biology and Therapeutics
- (2013) Masaru Katoh et al. MEDICINAL RESEARCH REVIEWS
- Functional Proteomics Defines the Molecular Switch Underlying FGF Receptor Trafficking and Cellular Outputs
- (2013) Chiara Francavilla et al. MOLECULAR CELL
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
- (2013) NATURE GENETICS
- Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
- (2013) Samuel Q. Li et al. PLoS One
- Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome
- (2012) A. Chase et al. HAEMATOLOGICA
- FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior
- (2012) Athina-Myrto Chioni et al. JOURNAL OF CELL BIOLOGY
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition
- (2012) Juliya Kalinina et al. STRUCTURE
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- Cell surface receptor expression patterns in osteosarcoma
- (2011) Sheref E. Hassan et al. CANCER
- FOXO1–FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma
- (2011) Jinglan Liu et al. MODERN PATHOLOGY
- PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma
- (2011) Amy D. Marshall et al. MOLECULAR CARCINOGENESIS
- Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT–SSX2
- (2011) C B Garcia et al. ONCOGENE
- Altered Splicing of FGFR1 Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer
- (2010) Darren C. Tomlinson et al. AMERICAN JOURNAL OF PATHOLOGY
- Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1–PI3K–Rac1 pathway
- (2010) S Kamura et al. BRITISH JOURNAL OF CANCER
- Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma
- (2010) Daniel Williamson et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
- (2009) Christine Y. Shiang et al. BREAST CANCER RESEARCH AND TREATMENT
- Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development
- (2009) Edoardo Missiaglia et al. GENES CHROMOSOMES & CANCER
- FGF19-induced Hepatocyte Proliferation Is Mediated through FGFR4 Activation
- (2009) Xinle Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
- (2009) Kirk R. Schultz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS
- (2009) Chitta Kasyapa et al. PROTEOMICS
- The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations
- (2009) E. D. Lew et al. Science Signaling
- FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities
- (2008) S Allerstorfer et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started